US EditionRakuten Medical Selected to Participate in FDA CEO Forum in San Diego
- Rakuten Medical, Inc. was selected by the U.S. Food and Drug Administration to participate in the FDA CEO Forum in San Diego on June 13, 2025.
- Minami Maeda represented Rakuten Medical at the panel to discuss modernization of the regulatory framework with FDA Commissioner Marty A. Makary.
- Rakuten Medical's Alluminox platform has the potential to transform cancer therapy in the U.S.
- The company is conducting a global Phase 3 clinical trial for its ASP-1929 photoimmunotherapy treatment for head and neck squamous cell carcinoma.
Insights by Ground AI
Does this summary seem wrong?
32 Articles
32 Articles
All
Left
2
Center
13
Right
Coverage Details
Total News Sources32
Leaning Left2Leaning Right0Center13Last UpdatedBias Distribution87% Center
Bias Distribution
- 87% of the sources are Center
87% Center
13%
C 87%
Factuality
To view factuality data please Upgrade to Premium
